Risedronate - Shiner Pharm

Drug Profile

Risedronate - Shiner Pharm

Alternative Names: Reosteo; Zhuo Rui bone

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmascience
  • Developer Shiner Pharm Corp
  • Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Male osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 30 Nov 2012 Taiwan FDA approves risedronate for the treatment of Male and Postmenopausal osteoporosis in Taiwan (Shiner Pharm webite, February 2016)
  • 30 Nov 2012 Launched for Male osteoporosis in Taiwan (PO) after November 2012
  • 30 Nov 2012 Launched for Postmenopausal osteoporosis in Taiwan (PO) after November 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top